康哲药业（00867.HK）今日盘中大涨5%，引起市场广泛关注。这一涨幅与公司近期公布的2025年中期业绩密切相关。
根据公司发布的中期业绩报告，2025年上半年康哲药业实现营收约40.0亿元，同比增长10.8%；净利润约9.3亿元，同比增长3.1%。这一业绩表现显示公司已走出国采阴霾，业绩重回上升轨道。值得注意的是，公司主要独家/品牌产品及创新产品全按药品销售收入达29.0亿元，同比增长20.6%，占总收入比重升至62.1%，成为拉动业绩增长的主力。
此外，康哲药业的创新战略也取得了显著进展。公司已有5款创新药成功商业化，并有望在年内获批两款新的创新产品。公司还在积极推进国际化战略，于7月在新加坡交易所完成第二上市。市场普遍认为，康哲药业的战略转型正在释放新的增长动力，这也是推动股价上涨的重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.